Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Homology Medicines, Inc. (NASDAQ: FIXX).

Full DD Report for FIXX

You must become a subscriber to view this report.

Recent News from (NASDAQ: FIXX)

Homology Medicines Presents Data on Platform's Ability to Target the Central and Peripheral Nervous System and Therapeutic Potential in the Rare Disease Metachromatic Leukodystrophy
Homology to Nominate a Clinical Development Candidate for MLD This Quarter and to Begin IND-Enabling Studies in 2019 BEDFORD, Mass., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today data demonstrating that Homology&#...
Source: GlobeNewswire
Date: November, 07 2018 07:30
Biotech IPOs on pace for near-record year - WSJ
The Wall Street Journal reports that the pace of biotech IPOs in on track for a near-record year, although many are riskier due to being in earlier stages of development. The public funding rush has been heavily influenced by the FDA's willingness to accelerate approval for promising drugs...
Source: SeekingAlpha
Date: October, 31 2018 09:03
Gene therapy players under pressure
The Nasdaq's selloff notwithstanding, most gene therapy stocks are in the red. This morning, Sangamo Therapeutics ( SGMO -21.1% ) reported data on SB-913 that disappointed investors. More news on: Sangamo Therapeutics, Inc., AVROBIO, MeiraGTx Holdings plc, Healthcare stocks news, Stocks ...
Source: SeekingAlpha
Date: September, 05 2018 10:58
Homology Medicines to Participate in Gene Editing Panel at Citi's Biotech Conference
BEDFORD, Mass. , Aug. 30, 2018 /PRNewswire/ -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today that Company management will participate in a panel on gene editing during Citi's 13th Annual Biotech Conference at 1:15 p.m. ET on Wednesday , September 5...
Source: PR Newswire
Date: August, 30 2018 08:30
FDA and NIH to loosen oversight of gene therapy development
Citing the need to safely expedite the development of gene therapies and the rapid scientific advances related to the gene editing, the FDA and NIH are backing trimmed down oversight of relevant clinical trials, specifically eliminating the duplication of oversight related to initial study...
Source: SeekingAlpha
Date: August, 16 2018 09:47
Synlogic up 7% on potential of SYNB1618 in phenylketonuria
Thinly traded micro cap Synlogic ( SYBX +6.5% ) is up on below-average volume in early trade. Yesterday, it announced the publication of preclinical data supporting the potential efficacy of SYNB1618 for treating phenylketonuria  (PKU), an inherited disorder characterized by the bu...
Source: SeekingAlpha
Date: August, 14 2018 10:30
Homology Medicines reports Q2 results
Homology Medicines (NASDAQ: FIXX ): Q2 EPS of -$0.35 More news on: Homology Medicines, Earnings news and commentary, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: August, 13 2018 16:25
Homology Medicines Reports Second Quarter 2018 Financial Results
BEDFORD, Mass. , Aug. 13, 2018 /PRNewswire/ -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today financial results for the quarter ended June 30, 2018 , and highlighted recent accomplishments. "During the quarter, we progressed IND-enabling stu...
Source: PR Newswire
Date: August, 13 2018 16:16
Biotech Stocks Are Tariff-Safe And Building Momentum
Biotech Pulse The first half of 2018 saw the Nasdaq Biotechnology Index ( IBB ) make a 52-week high in January and thereafter enter a 5-month consolidation period. Even though the index managed to eke out only a +3% gain in the first half, the second-half has started on a brisk note...
Source: SeekingAlpha
Date: July, 23 2018 10:26
Homology Medicines Announces Peer-Reviewed Publication Demonstrating Efficient and Precise In Vivo Gene Editing Capabilities of Nuclease-Free Technology Platform
BEDFORD, Mass. , July 16, 2018 /PRNewswire/ -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today a peer-reviewed publication demonstrating that Homology's technology induces efficient and precise in vivo gene editing. The publication, by senior a...
Source: PR Newswire
Date: July, 16 2018 16:01


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on FIXX.

About Homology Medicines, Inc. (NASDAQ: FIXX)

Logo for Homology Medicines, Inc. (NASDAQ: FIXX)

Not available


Contact Information



    Current Share Structure


      Recent Filings from (NASDAQ: FIXX)

      Amendment to a previously filed Form 4
      Filing Type: 4/AFiling Source: edgar
      Filing Date: May, 16 2018
      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 14 2018
      Statement of beneficial ownership of common stock by certain persons
      Filing Type: SC 13GFiling Source: edgar
      Filing Date: April, 11 2018
      Filing by person(s) reporting owned shares of common stock in a public company >5%
      Filing Type: SC 13DFiling Source: edgar
      Filing Date: April, 06 2018
      Amendment to a previously filed Form 4
      Filing Type: 4/AFiling Source: edgar
      Filing Date: April, 04 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: April, 03 2018
      Filing Type: CT ORDERFiling Source: edgar
      Filing Date: March, 30 2018
      Prospectus filed under Rule 424(b)(4)
      Filing Type: 424B4Filing Source: edgar
      Filing Date: March, 29 2018
      Securities offered to employees under employee benefit plans
      Filing Type: S-8Filing Source: edgar
      Filing Date: March, 29 2018
      Amendment to general form for registration of securities under the Securities Act of 1933
      Filing Type: S-1/AFiling Source: edgar
      Filing Date: March, 27 2018



      Daily Technical Chart for (NASDAQ: FIXX)

      Daily Technical Chart for (NASDAQ: FIXX)

      Stay tuned for daily updates and more on (NASDAQ: FIXX)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: FIXX)

      Do your DD and if you choose, be ready to go!


      The Research: All source information contained in this email is from the public sources mentioned below.



      Thank you

      DD Report



      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in FIXX is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of FIXX and does not buy, sell, or trade any shares of FIXX. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: